The groundbreaking success of Viagra undeniably reshaped the drug landscape, but investing in companies strongly reliant on unbranded versions presents a complex picture. Despite early profits were significant, the end of patents and the appearance of cheaper alternatives have eroded market share. Consequently, a thorough analysis of ongoing income